Olema Pharmaceuticals inc (NAS:OLMA)
$ 6.15 -0.17 (-2.69%) Market Cap: 466.46 Mil Enterprise Value: 253.39 Mil PE Ratio: 0 PB Ratio: 1.82 GF Score: 38/100

Olema Pharmaceuticals Inc at Credit Suisse Healthcare Conference Transcript

Nov 09, 2022 / 05:10PM GMT
Release Date Price: $2.97 (-5.11%)
Rich Law
Credit Suisse Group AG - Analyst

Okay, let's get going. Good morning, my name is Rich Law. I'm a Senior Biotech Analyst at CS. I'd like to welcome our next session Olema for this fireside chat. We're joined by Sean Bohen, President and CEO of Olema. So, Sean, welcome.

Sean Bohen
Olema Pharmaceuticals, Inc. - President & CEO

Thank you, Rich.

Rich Law
Credit Suisse Group AG - Analyst

Before we go into the Q&A, any opening remarks that you want to give?

Sean Bohen
Olema Pharmaceuticals, Inc. - President & CEO

Sure, I mean I think Olema is a women's cancer-focused company. We have a research pipeline as well as our single current clinical asset, which is OP-1250. It's a complete estrogen receptor antagonist and SERD for ER+ breast cancer. And that program has progressed really nicely.

We just presented our updated Phase 1b data and dose selection at ENA in Barcelona. We will at San Antonio. The titles are out. We will present our palbo

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot